Vyant Bio and OrganoTherapeutics Announce Strategic Collaboration to Discover Therapeutics to Treat Parkinson’s Disease
Published on: Tuesday 29 March 2022
Cherry Hill, N.J. and Esch-sur-Alzette, Luxembourg, March 29, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders and OrganoTherapeutics, a developer of proprietary patient-specific organoids that recapitulate Parkinson’s Disease (PD) pathology, announced today they have entered into a collaboration agreement to work toward accelerating the d
RELATED NEWS
